Published in Hepatitis Weekly, January 23rd, 2006
Study 1: According to recent research from the United States, prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus (VSV) virotherapy for advanced hepatocellular carcinoma (HCC) in immune-competent rats.
"VSV is a negative-strand RNA virus with intrinsic oncolytic specificity due to substantially attenuated antiviral responses in many tumors. We have recently reported that recombinant VSV vector can be used as an effective oncolytic agent to safely treat multifocal HCC in the livers of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.